Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://bfu-tournaments.com/index.php/news/11293
Are you over 18 and want to see adult content?
A complete backup of https://komikmama.net/id-memorize-sap-chapter-34/
Are you over 18 and want to see adult content?
A complete backup of https://www.mundotecnico.info/viewtopic.php?t=4859
Are you over 18 and want to see adult content?
A complete backup of https://teniesonline.gr/movies/?m=Mulan&t=tt4566758
Are you over 18 and want to see adult content?
A complete backup of https://www.rottentomatoes.com/top-tv/
Are you over 18 and want to see adult content?
A complete backup of https://www.mutaz.net/free-programs/en/download/?299
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of aristocraziawebzine.com
Are you over 18 and want to see adult content?
Text
EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications.NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onSTEVEN GILLIS
Steven Gillis, Ph.D., Board Chairman. Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. BOB MORE | EGENESIS BIO Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.”. Prior to that, he was a General Partner with Frazier Healthcare Ventures and DomainAssociates. Mr.
EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications.NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onSTEVEN GILLIS
Steven Gillis, Ph.D., Board Chairman. Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. BOB MORE | EGENESIS BIO Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.”. Prior to that, he was a General Partner with Frazier Healthcare Ventures and DomainAssociates. Mr.
SCIENCE | EGENESIS BIO Leveraging our platform, we’ve been able to address previously unbeatable biological hurdles in the transplantation field. Our approach is to address both infectious disease risk as well as molecular incompatibilities between species in order to develop safe and durable xeno organs forDEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications. INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PUBLICATIONS
Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT (2014) Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies CONTACT US | EGENESIS BIO eGenesis Headquarters 300 Technology Square, Suite 301 Cambridge, MA 02139. eGenesis New York Office 7 Times Sq. 43rd Floor New York, NY 10036. For general inquiries, please contact: info@egenesisbio.com For media inquiries, please contact: media@egenesisbio.comTRANSPLANTATION
The Hope of Xenotransplantation. Xenotransplantation, or the transplantation of organs, tissues and cells between different species, has the potential to address the current organ crisis, with the pig currently considered to be the best potential donor of biologic material for humans. In 1997, concerns about the porcine endogenous retrovirus EGENESIS EXPANDS RESEARCH COLLABORATION WITH MASSACHUSETTS eGenesis Expands Research Collaboration with Massachusetts General Hospital. CAMBRIDGE, Mass., June 2, 2020 — eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced theexpansion
BOARD OF DIRECTORS
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PRESS RELEASES
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to EGENESIS CO-FOUNDER LUHAN YANG NAMED YOUNG GLOBAL LEADER Luhan Yang Joins Next Generation Scientists and Breakthrough Technology Entrepreneurs in Young Global Leader Class of 2017. Cambridge, Mass. – March 15, 2017 – Co-founder and Chief Scientific Officer, Luhan Yang, Ph.D., has been honored as a Young Global Leader with the class of 2017. This honor is granted by the World Economic Forum each year to recognize the most distinguishedEGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications.NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onSTEVEN GILLIS
Steven Gillis, Ph.D., Board Chairman. Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. BOB MORE | EGENESIS BIO Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.”. Prior to that, he was a General Partner with Frazier Healthcare Ventures and DomainAssociates. Mr.
EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications.NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onSTEVEN GILLIS
Steven Gillis, Ph.D., Board Chairman. Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. BOB MORE | EGENESIS BIO Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.”. Prior to that, he was a General Partner with Frazier Healthcare Ventures and DomainAssociates. Mr.
SCIENCE | EGENESIS BIO Leveraging our platform, we’ve been able to address previously unbeatable biological hurdles in the transplantation field. Our approach is to address both infectious disease risk as well as molecular incompatibilities between species in order to develop safe and durable xeno organs forDEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications. INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PUBLICATIONS
Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT (2014) Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies CONTACT US | EGENESIS BIO eGenesis Headquarters 300 Technology Square, Suite 301 Cambridge, MA 02139. eGenesis New York Office 7 Times Sq. 43rd Floor New York, NY 10036. For general inquiries, please contact: info@egenesisbio.com For media inquiries, please contact: media@egenesisbio.comTRANSPLANTATION
The Hope of Xenotransplantation. Xenotransplantation, or the transplantation of organs, tissues and cells between different species, has the potential to address the current organ crisis, with the pig currently considered to be the best potential donor of biologic material for humans. In 1997, concerns about the porcine endogenous retrovirus EGENESIS EXPANDS RESEARCH COLLABORATION WITH MASSACHUSETTS eGenesis Expands Research Collaboration with Massachusetts General Hospital. CAMBRIDGE, Mass., June 2, 2020 — eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced theexpansion
BOARD OF DIRECTORS
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PRESS RELEASES
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to EGENESIS CO-FOUNDER LUHAN YANG NAMED YOUNG GLOBAL LEADER Luhan Yang Joins Next Generation Scientists and Breakthrough Technology Entrepreneurs in Young Global Leader Class of 2017. Cambridge, Mass. – March 15, 2017 – Co-founder and Chief Scientific Officer, Luhan Yang, Ph.D., has been honored as a Young Global Leader with the class of 2017. This honor is granted by the World Economic Forum each year to recognize the most distinguishedEGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. SCIENCE | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications. CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.TRANSPLANTATION
The Hope of Xenotransplantation. Xenotransplantation, or the transplantation of organs, tissues and cells between different species, has the potential to address the current organ crisis, with the pig currently considered to be the best potential donor of biologic material for humans. In 1997, concerns about the porcine endogenous retrovirus LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onEGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to ABOUT US | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis. SCIENCE | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.DEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications. CAREERS | EGENESIS BIO Careers | eGenesis Bio. Careers. We are empowered. We are entrepreneurial. We respect and value science for transforming patient lives. “Every day patients are waiting because there is a lack of suitable available organs for transplantation. We are making exciting scientific contributions to the gene editing field, by advancing thefield of
NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to INVESTORS | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.TRANSPLANTATION
The Hope of Xenotransplantation. Xenotransplantation, or the transplantation of organs, tissues and cells between different species, has the potential to address the current organ crisis, with the pig currently considered to be the best potential donor of biologic material for humans. In 1997, concerns about the porcine endogenous retrovirus LEADERSHIP | EGENESIS BIO eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.PAUL SEKHRI
Paul Sekhri, President & Chief Executive Officer. Mr. Sekhri is the president and chief executive officer of eGenesis. Mr. Sekhri brings to eGenesis decades of experience leading life sciences companies, including those with a focus on immunology, and has been a director onDEVELOPMENT
eGenesis is on the forefront of pioneering clinical studies for solid organ xenotransplantation. Our lead programs are for kidney and islet cell transplantation, which are both currently in preclinical development. eGenesis has a platform technology that allows for a broad pipeline of applications.NEWS | EGENESIS BIO
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells toPUBLICATIONS
Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT (2014) Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies CONTACT US | EGENESIS BIO eGenesis Headquarters 300 Technology Square, Suite 301 Cambridge, MA 02139. eGenesis New York Office 7 Times Sq. 43rd Floor New York, NY 10036. For general inquiries, please contact: info@egenesisbio.com For media inquiries, please contact: media@egenesisbio.comTRANSPLANTATION
The Hope of Xenotransplantation. Xenotransplantation, or the transplantation of organs, tissues and cells between different species, has the potential to address the current organ crisis, with the pig currently considered to be the best potential donor of biologic material for humans. In 1997, concerns about the porcine endogenous retrovirus CLINICAL ADVISORY BOARD eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.ELIZABETH ROBERTS
Elizabeth Roberts, Chief People Officer. Ms. Roberts comes to eGenesis as the chief people officer, to leverage her specialty of building amazing biotech teams to move the needle on human health. Prior to eGenesis, Ms. Roberts was a Partner & Head of People at Ulysses Diversified holdings, a unique investment and incubation studiofocused on
ARIEL JASIE
Ariel Jasie, Chief Business Officer & General Counsel. Mr. Jasie is the chief business officer and general counsel of eGenesis, and is responsible for overseeing all business development and legal activities. Before eGenesis, Mr. Jasie most recently worked at Dermavant Sciences where he served as the chief business and strategyofficer.
BOB MORE | EGENESIS BIO Mr. Bob More is a managing director at Alta Partners. Previously, he was a senior advisor for The Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.”. Prior to that, he was a General Partner with Frazier Healthcare Ventures and DomainAssociates. Mr.
STEVEN GILLIS
Steven Gillis, Ph.D., Board Chairman. Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies.* About Us
* Leadership
* Board of Directors * Scientific Advisory Board * Clinical Advisory Board* Investors
* Science
* Transplantation
* Development
* Publications
* News
* Press Releases
* Press Coverage
* Careers
* Contact
* MENU Menu
*
Video Player
Media error: Format(s) not supported or source(s) not foundDownload File:
https://www.egenesisbio.com/wp-content/uploads/homepage-video-sm.mp400:00
00:00 | 00:00
Use Up/Down Arrow keys to increase or decrease volume. EGENESIS STRIVES TO CREATE A WORLD with no shortage of human transplantable organs113,717
People in the U.S. need a life saving organ transplantOUR MISSION
ENGINEERING HOPE
PROBLEM
ORGAN TRANSPLANTATION IS CURRENTLY FAILING TO MEET CRITICAL PATIENT NEEDS DUE TO A MASSIVE GAP BETWEEN ORGAN DEMAND AND SUPPLY GLOBALLY.SOLUTION
AS LEADERS IN GENE EDITING AND GENOME ENGINEERING, WE ARE UNIQUELY POSITIONED TO ADDRESS THE ORGAN CRISIS WITH OUR UNPARALLELED, MULTIPLEXED GENE EDITING PLATFORM.IMPACT
WE ARE DRIVEN TO PROVIDE HOPE TO THOUSANDS OF PATIENTS WITH END-STAGE ORGAN DISEASE BY PROVIDING AN ALTERNATIVE SOURCE OF SAFE AND EFFECTIVE HUMAN-COMPATIBLE ORGANS.OUR SCIENCE
OUR PROCESS
GENE ENGINEERING
SINGLE CELL CLONING
SOMATIC CELL NUCLEAR / EMBRYO TRANSFERORGAN PROCUREMENT
TRANSPLANTATION
OUR DEVELOPMENT
CAREERS
ARE YOU PASSIONATE ABOUT ENGINEERING BIOLOGY TO POSITIVELY IMPACT HUMAN LIVES? FIND THE LATEST CAREER OPPORTUNITIES AT EGENESIS.JOIN US
Latest News
April 1, 2021
EGENESIS EXPANDS RESEARCH COLLABORATION WITH LEADING ACADEMIC MEDICALCENTER
Read more
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png0 0 3mediaweb
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png 3mediaweb2021-04-01 08:00:312021-04-01 08:00:42eGenesis Expands Research Collaboration with Leading Academic Medical CenterMarch 4, 2021
EGENESIS APPOINTS VETERAN FINANCIAL EXECUTIVE, SAPNA SRIVASTAVA, PH.D., AS CHIEF FINANCIAL OFFICERRead more
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png0 0 3mediaweb
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png 3mediaweb2021-03-04 07:59:422021-03-04 07:59:33eGenesis Appoints Veteran Financial Executive, Sapna Srivastava, Ph.D., as ChiefFinancial Officer
March 2, 2021
EGENESIS ANNOUNCES $125 MILLION SERIES C FINANCINGRead more
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png0 0 3mediaweb
https://www.egenesisbio.com/wp-content/uploads/eGenesis-New-Logo-2020-3.png 3mediaweb2021-03-02 08:00:582021-03-01 17:24:28eGenesis Announces $125 Million Series C FinancingOUR NEWS
PRESS COVERAGE
OUR PRESS COVERAGE
MISSION STATEMENT
eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.CONTACT US
EGENESIS HEADQUARTERS 300 Technology SquareSuite 301
Cambridge, MA 02139
info@egenesisbio.com eGenesis New York Office7 Times Sq.
43rd Floor
New York, NY 10036
QUICK LINKS
* About Us
* Science
* News
* Careers
* Contact
Biotech Web Design Agency © 2021 - eGenesis Scroll to topDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0